Onset of various CNS inflammatory demyelination diseases following COVID-19 vaccinationsResearch article Published on 2022-12-012022-10-05 Journal: Multiple sclerosis and related disorders [Category] 진단, [키워드] Central nervous system CNS collected COVID-19 COVID-19 vaccination Demyelinating disease demyelination disease disease disease manifestation disease onset disorder Inflammatory investigated MOG MOG antibody-associated disease multiple sclerosis Neuromyelitis optica spectrum disorder observation Onset proportion Registered Result susceptible individuals vaccination [DOI] 10.1016/j.msard.2022.104141 [Article Type] Research article
Investigation of SARS-CoV-2 nucleocapsid protein interaction with a specific antibody by combined spectroscopic ellipsometry and quartz crystal microbalance with dissipationArticle Published on 2022-11-152022-11-15 Journal: Journal of Colloid and Interface Science [Category] COVID19(2023년), SARS, 진단, [키워드] affected antibody Antibody and antigen interaction Antibody bivalent binding Antibody flexibility Antigen binding complex conformational change distribution Fab fragment immune complex Immune complexes immunosensor information Interaction investigation polyclonal produced Protein Quantitative quartz Quartz crystal microbalance with dissipation (QCM-D) Registered SARS-CoV-2 SARS-CoV-2 nucleocapsid Spectroscopic ellipsometry. was determined was used [DOI] 10.1016/j.jcis.2022.06.119 PMC 바로가기
Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasiaArticle Published on 2022-11-072022-11-16 Journal: Orphanet Journal of Rare Diseases [Category] 유전자 메커니즘, [키워드] analysis Angiogenesis assigned Biomarkers bleeding Blood center double-blind doxycycline Effectiveness ENG Epistaxis Frequency heart failure help hemorrhage Hemorrhagic Hereditary Hereditary hemorrhagic telangiectasia Hereditary hemorrhagic telangiectasia. HHT IL-6 Inflammatory intravenous limitations Liver disease malformation marker mechanism Michael morbidity no significant difference not significantly different observation pathway Patient Placebo placebo-controlled provided Quality of life Randomized controlled trial Randomly RBC recruited Registered Registration secondary significantly higher stroke telangiectasia therapy Toronto Treatment treatment period Trial VEGF [DOI] 10.1186/s13023-022-02539-8 PMC 바로가기
Antiviral efficacy of cerium oxide nanoparticlesArticle Published on 2022-11-052022-11-15 Journal: Scientific Reports [Category] SARS, 치료제, [키워드] Antiviral antiviral activity antiviral efficacy candidate Concentration coronavirus SARS-CoV-2 cytotoxicity decrease Effect Efficacy evidenced expected gastroenteritis highest Influenza virus Ion mechanism MS2 bacteriophage Nanomaterial no decrease non-enveloped virus nonspecific plaque forming unit Registered released sensitivity significantly lower tested virus virus viruses were assessed [DOI] 10.1038/s41598-022-23465-6 PMC 바로가기
Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trialArticle Published on 2022-11-032022-11-16 Journal: Journal of Translational Medicine [Category] 비임상, [키워드] 1:1 Administered administration adverse event age Analysis animal model Anti-inflammatory assigned baseline Borg change changes in Chronic diseases clinical trial clinically COVID COVID pneumonia COVID-19 defined Diagnosis discharged double-blind Dyspnea Effect effective Efficacy Endpoint enrolled evaluated female female gender FEV first symptom FVC impairment increase in indicated Infection initial LLC lung damage Lung fibrosis Lung function Lungs mMRC moderate NCT04527354 offer past medical history Patient patients pharmacological treatment Placebo placebo group placebo-controlled clinical trial placebo-controlled trial Post-COVID rehabilitation predicted Prevent Primary outcome proportion pulmonary dysfunction pulmonary fibrosis Pulmonary function questionnaire Randomized Randomly reduction in Registered rehabilitation risk factor Russia SARS-CoV-2 secondary shown significant decrease significant difference stratified Support Symptoms Tolerability Treamid. Treatment Trial was done women [DOI] 10.1186/s12967-022-03660-9 PMC 바로가기
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trialArticle Published on 2022-11-012022-11-15 Journal: International Journal of Infectious Diseases [Category] 진단, [키워드] Administered adverse event age binding antibody clinical trial Comorbidities Comorbidity COVID-19 infection demonstrated dose double-blind elicited General population High dose High-dose immune response immunization immunogenicity immunosenescence Mild mortality rates MVC-COV1901 vaccine negative correlation Neutralizing Older older adult Older adults participant Phase 2 protein subunit vaccine Randomized regimen Registered robust Safety SARS-CoV-2. stratified subject Trial Vaccine [DOI] 10.1016/j.ijid.2022.08.021 PMC 바로가기
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyArticle Published on 2022-10-272022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Ad26.COV2.S Ad26.COV2.S vaccine age Analysis anti-SARS-CoV-2 Anti-spike antibody Antibody Response Antiretroviral therapy approved assays BNT162b2 CD4+ T-cell CD8+ T-cell ChAdOx1-S comparable Concentration conducted Control controls COVID-19 defined ELISPOT Endpoint Environment Final generally mild geometric HIV HIV-negative IFN-γ immunogenic immunogenicity Increased IQR less maintain male marker median age mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based vaccines Netherland Netherlands of BNT162b2 PLWH predicted primary endpoint prospective cohort study Public reactogenicity receiving recipients reduced Registered remained required response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 spike peptide SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Serious Adverse Events serological response Sex suppressed T-cell Response the median the vaccine Trial vaccination Vaccine vaccine group Viral load with HIV [DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
Screening and evaluation of cytotoxicity and antiviral effects of secondary metabolites from water extracts of Bersama abyssinica against SARS-CoV-2 DeltaArticle Published on 2022-10-262022-11-15 Journal: BMC Complementary Medicine and Therapies [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] Acetate activities Analysis Anti-viral anti-viral agents antioxidant antiviral activity Antiviral effect Asthma bacterial respiratory infections Bersama abyssinica bioactive compounds bronchitis BSL-3 component Compound Concentration conducted coronavirus Coviba Dawa COVID-19 COVID-19 symptoms cytotoxicity Delta delta variant determine ether experiment fraction in vitro ingredient Isolation level 3 medication methanol Phenols polar procedure propionate Registered respiratory disorder SARS-CoV-2 Screening Secondary Metabolite Standard Tanzania temperature tested the SARS-CoV-2 Traditional Traditional medicine. treat VERO E6 cells viral pathogen virus was done was obtained water [DOI] 10.1186/s12906-022-03754-3 PMC 바로가기
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) StudyArticle Published on 2022-10-262022-11-15 Journal: mBio [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome addition adopted Adverse adverse event AEs amplification antibodies CCP Clinical outcome competing Concentration conducted convalescent convalescent plasma coronavirus COVID-19 death defined donors dose response Effectiveness eligible evaluate evaluated event Fisher Gray hazard ratio heterogeneity high-risk population hospital hospital discharge immunology Inconclusive Infection Lower Mortality NAb Neutralizing antibodies neutralizing antibodies. neutralizing antibody observational study occurred participant Patient positive primary clinical outcome randomized control trial receiving Registered Research Respiratory Support Result risk SAEs SARS-CoV-2 SARS-CoV-2 nucleic acid screened Secondary outcomes severe COVID-19 Standard of care Support Symptom therapeutic therapy time titer Treatment [DOI] 10.1128/mbio.01751-22 PMC 바로가기
COVID-19 prevalence and infection control measures at homeless shelters and hostels in high-income countries: a scoping reviewArticle Published on 2022-10-152022-11-16 Journal: Systematic Reviews [Category] 변종, [키워드] absence Analysis applied assessment Asymptomatic conducted country COVID-19 COVID-19 outbreak COVID-19 pandemic Critical database demographics disease events Evidence exclusion Factor global health Health Homeless population Homeless shelters impacted implementation infection control limitation mapped measure Measures offer outbreak outcome people experiencing homelessness populations portal Prevalence prevalence of COVID-19 prevention protocol public health Registered Research screened Shelter workers. Spread the WHO university variant York [DOI] 10.1186/s13643-022-02089-x PMC 바로가기